Cargando…
Deciding when to stop: efficient experimentation to learn to predict drug-target interactions
BACKGROUND: Active learning is a powerful tool for guiding an experimentation process. Instead of doing all possible experiments in a given domain, active learning can be used to pick the experiments that will add the most knowledge to the current model. Especially, for drug discovery and developmen...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495685/ https://www.ncbi.nlm.nih.gov/pubmed/26153434 http://dx.doi.org/10.1186/s12859-015-0650-9 |
_version_ | 1782380290349465600 |
---|---|
author | Temerinac-Ott, Maja Naik, Armaghan W Murphy, Robert F |
author_facet | Temerinac-Ott, Maja Naik, Armaghan W Murphy, Robert F |
author_sort | Temerinac-Ott, Maja |
collection | PubMed |
description | BACKGROUND: Active learning is a powerful tool for guiding an experimentation process. Instead of doing all possible experiments in a given domain, active learning can be used to pick the experiments that will add the most knowledge to the current model. Especially, for drug discovery and development, active learning has been shown to reduce the number of experiments needed to obtain high-confidence predictions. However, in practice, it is crucial to have a method to evaluate the quality of the current predictions and decide when to stop the experimentation process. Only by applying reliable stopping criteria to active learning can time and costs in the experimental process actually be saved. RESULTS: We compute active learning traces on simulated drug-target matrices in order to determine a regression model for the accuracy of the active learner. By analyzing the performance of the regression model on simulated data, we design stopping criteria for previously unseen experimental matrices. We demonstrate on four previously characterized drug effect data sets that applying the stopping criteria can result in upto 40 % savings of the total experiments for highly accurate predictions. CONCLUSIONS: We show that active learning accuracy can be predicted using simulated data and results in substantial savings in the number of experiments required to make accurate drug-target predictions. |
format | Online Article Text |
id | pubmed-4495685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44956852015-07-09 Deciding when to stop: efficient experimentation to learn to predict drug-target interactions Temerinac-Ott, Maja Naik, Armaghan W Murphy, Robert F BMC Bioinformatics Research Article BACKGROUND: Active learning is a powerful tool for guiding an experimentation process. Instead of doing all possible experiments in a given domain, active learning can be used to pick the experiments that will add the most knowledge to the current model. Especially, for drug discovery and development, active learning has been shown to reduce the number of experiments needed to obtain high-confidence predictions. However, in practice, it is crucial to have a method to evaluate the quality of the current predictions and decide when to stop the experimentation process. Only by applying reliable stopping criteria to active learning can time and costs in the experimental process actually be saved. RESULTS: We compute active learning traces on simulated drug-target matrices in order to determine a regression model for the accuracy of the active learner. By analyzing the performance of the regression model on simulated data, we design stopping criteria for previously unseen experimental matrices. We demonstrate on four previously characterized drug effect data sets that applying the stopping criteria can result in upto 40 % savings of the total experiments for highly accurate predictions. CONCLUSIONS: We show that active learning accuracy can be predicted using simulated data and results in substantial savings in the number of experiments required to make accurate drug-target predictions. BioMed Central 2015-07-09 /pmc/articles/PMC4495685/ /pubmed/26153434 http://dx.doi.org/10.1186/s12859-015-0650-9 Text en © Temerinac-Ott et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Temerinac-Ott, Maja Naik, Armaghan W Murphy, Robert F Deciding when to stop: efficient experimentation to learn to predict drug-target interactions |
title | Deciding when to stop: efficient experimentation to learn to predict drug-target interactions |
title_full | Deciding when to stop: efficient experimentation to learn to predict drug-target interactions |
title_fullStr | Deciding when to stop: efficient experimentation to learn to predict drug-target interactions |
title_full_unstemmed | Deciding when to stop: efficient experimentation to learn to predict drug-target interactions |
title_short | Deciding when to stop: efficient experimentation to learn to predict drug-target interactions |
title_sort | deciding when to stop: efficient experimentation to learn to predict drug-target interactions |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495685/ https://www.ncbi.nlm.nih.gov/pubmed/26153434 http://dx.doi.org/10.1186/s12859-015-0650-9 |
work_keys_str_mv | AT temerinacottmaja decidingwhentostopefficientexperimentationtolearntopredictdrugtargetinteractions AT naikarmaghanw decidingwhentostopefficientexperimentationtolearntopredictdrugtargetinteractions AT murphyrobertf decidingwhentostopefficientexperimentationtolearntopredictdrugtargetinteractions |